Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

discovered and initially

developed by Roche; EntreMed has an exclusive worldwide license to

develop and commercialize the drug.

-- MKC-1 is currently in multiple Phase 1 and Phase 2 clinical trials,

including metastatic breast cancer (MBC), non-small cell lung cancer

(NSCLC), hematological cancers, ovarian and endometrial cancer, and

pancreatic cancer. Milestones for MKC-1 in 2008 include reporting

results for the single agent MKC-1 MBC study (2Q08); presentation of

interim data for MKC-1/Alimta combination study in NSCLC (2Q08);

presentation of Phase 1 data for MKC-1 in hematological cancers (2H08);

initiation of a Phase 1 MKC-1 continuous dosing study (2Q08); and

presentation of interim data for a Phase 2 study in pancreatic cancer

(4Q08).

-- ENMD-1198 is a potent, orally-active, antimitotic agent discovered at

EntreMed that causes cell cycle arrest and apoptosis in tumor cells.

ENMD-1198 has shown pronounced antitumor activity and survival

increases in multiple preclinical models, including a substantial

decrease in tumor cell proliferation and angiogenesis in a breast

cancer model; synergistic effects in combination with vincristine that

prolonged survival in preclinical leukemia models; and a three-fold

increase in survival compared to standard-of-care Cisplatin in a

preclinical NSCLC model.

-- A Phase 1b dose-escalation clinical trial is currently underway to

evaluate ENMD-1198 in patients with refractory solid tumors. Completion

of the study is expected around mid-2008 with a further trial expected

in the second half of 2008. ENMD-1198 milestones for 2008 include

completion of Phase 1b enrollment (2Q/3Q08); initiation of an expanded

Phase 1 or Phase 2 trial (3Q/4Q08); and the reporting of data for the

Phase 1b clinical
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
(Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... , ... ... ... ...
... , ... symposium to unveil study aimed at ensuring global food security and sustainability. , ... Washington (PRWEB) -- On ... sustainably double agricultural output and improve storage and distribution to eliminate the global productivity ...
... ... ... ... ...
Cached Biology Technology:Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 2Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 3Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 4Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 5Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 6Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 7Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 8Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 9Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 10Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 11Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 12Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 13Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 14Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 15Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 16Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 17Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 18Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 19Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 20Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 21Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 22Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 23Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 24Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 25Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 26Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 27Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 28Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 29Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 30Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs 2Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs 3Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 2Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 3Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 4Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 5
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... physics now becomes easier with the formal launch of ... from the American Physical Society. Physics will highlight and ... publications of Physical Review Letters and the ... will keep readers apprised of important new articles as ...
... information, as detectives, historians and identity thieves well ... treasures, University of Delaware researchers have found. ... UD,s Delaware Biotechnology Institute analyzed the cellular waste ... discovered formerly hidden relationships between genes and the ...
... of Oregon,s Climate Leadership Initiative, the need to address ... Bob Doppelt says in his new book requires a ... The 240-page book published by London-based Earthscan Publications Ltd. ... private sector, but its content is accessible to "anyone ...
Cached Biology News:American Physical Society announces Physics, a new, free, online publication 2Using novel tool, UD researchers dig through cell 'trash' and find treasure 2Using novel tool, UD researchers dig through cell 'trash' and find treasure 3'No time to lose' to start thinking sustainability 2
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... CellBIND surface is produced by a ... more hydrophilic surface giving more consistent, ... and yields. CellBIND enhances cell attachment ... reduced serum or serum-free medium. • ...
Cell Culture Flask, 75 cm, treated polystyrene...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
Biology Products: